Comparative Pharmacology
Head-to-head clinical analysis: AMIKIN versus GENTAFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIKIN versus GENTAFAIR.
AMIKIN vs GENTAFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic